- Home
- TWO vs EWTX Comparison
TWO vs EWTX Comparison
Compare TWO & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWO
- EWTX
- Stock Information
- Founded
- TWO 2009
- EWTX 2017
- Country
- TWO United States
- EWTX United States
- Employees
- TWO N/A
- EWTX N/A
- Industry
- TWO Real Estate Investment Trusts
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- TWO Real Estate
- EWTX Health Care
- Exchange
- TWO Nasdaq
- EWTX Nasdaq
- Market Cap
- TWO 1.1B
- EWTX 1.2B
- IPO Year
- TWO 2009
- EWTX 2021
- Fundamental
- Price
- TWO $10.75
- EWTX $14.47
- Analyst Decision
- TWO Buy
- EWTX Buy
- Analyst Count
- TWO 8
- EWTX 8
- Target Price
- TWO $13.25
- EWTX $39.63
- AVG Volume (30 Days)
- TWO 1.8M
- EWTX 971.2K
- Earning Date
- TWO 07-29-2025
- EWTX 08-07-2025
- Dividend Yield
- TWO 16.76%
- EWTX N/A
- EPS Growth
- TWO N/A
- EWTX N/A
- EPS
- TWO N/A
- EWTX N/A
- Revenue
- TWO $370,696,000.00
- EWTX N/A
- Revenue This Year
- TWO N/A
- EWTX N/A
- Revenue Next Year
- TWO N/A
- EWTX N/A
- P/E Ratio
- TWO N/A
- EWTX N/A
- Revenue Growth
- TWO N/A
- EWTX N/A
- 52 Week Low
- TWO $10.16
- EWTX $10.60
- 52 Week High
- TWO $14.28
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- TWO 42.69
- EWTX 43.66
- Support Level
- TWO $10.77
- EWTX $14.87
- Resistance Level
- TWO $11.00
- EWTX $15.68
- Average True Range (ATR)
- TWO 0.26
- EWTX 0.69
- MACD
- TWO 0.04
- EWTX 0.02
- Stochastic Oscillator
- TWO 63.19
- EWTX 25.61
About TWO Two Harbors Investment Corp
Two Harbors Investment Corp is a real estate investment trust focused on investing in, financing, and managing residential mortgage-backed securities, or RMBS; residential mortgage loans; mortgage servicing rights; and commercial real estate. The majority of the company's investment portfolio is split between agency RMBS purchased from government-sponsored enterprises and nonagency RMBS. Two Harbors derives nearly all of its revenue in the form of interest income collected from its investments. The majority of this income is generated by available-for-sale securities, while residential mortgage loans held for investment in securitization trusts also contribute a sizable amount.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.